NLS Book Value Per Share from 2010 to 2024

NLSPW Stock

USD 0.01 0 22.22%

NLS Pharmaceutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to -0.24 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of NLS Pharmaceutics AG according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(0.23)

Current Value

(0.24)

Quarterly Volatility

0.45500281

Credit Downgrade

Yuan Drop

Covid

Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.

Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of NLS Pharmaceutics AG over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. NLS Pharmaceutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (9.40) X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

NLS Book Value Per Share Regression Statistics

	Arithmetic Mean	(0.58)
	Coefficient Of Variation	(78.67)
	Mean Deviation	0.28
	Median	(0.66)
	Standard Deviation	0.46
	Sample Variance	0.21
	Range	2.0309
	R-Value	0.31
	Mean Square Error	0.20
	R-Squared	0.1
	Significance	0.26
	Slope	0.03
	Total Sum of Squares	2.90

NLS Book Value Per Share History

	2024	-0.24
	2023	-0.23
	2022	0.17
	2021	0.0368
	2020	-1.86
	2019	-0.55
	2018	-0.75

Other Fundumenentals of NLS Pharmaceutics

Tangible Book Value Per Share

NLS Pharmaceutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Net Receivables	Short Long Term Debt	Capital Stock	Short Term Debt	Current Deferred Revenue
Total Assets		0.89	-0.78	-0.46	0.07	-0.33	0.3	-0.63	0.42	0.99	0.61	0.53	0.13	0.46	0.6	0.38	0.51
Total Stockholder Equity	0.89		-0.82	-0.31	0.06	-0.39	0.4	-0.73	0.42	0.89	0.63	0.32	0.39	0.39	0.47	0.55	0.43
Net Debt	-0.78	-0.82		0.74	-0.58	0.84	-0.82	0.81	0.15	-0.73	-0.1	-0.69	-0.59	-0.77	-0.75	-0.48	-0.8
Retained Earnings	-0.46	-0.31	0.74		-0.79	0.82	-0.8	0.5	0.54	-0.44	0.35	-0.98	-0.19	-0.82	-0.92	-0.17	-0.85
Accounts Payable	0.07	0.06	-0.58	-0.79		-0.88	0.91	-0.22	-0.82	0.0	-0.69	0.65	0.53	0.85	0.67	0.03	0.83
Long Term Debt	-0.33	-0.39	0.84	0.82	-0.88		-0.98	0.66	0.66	-0.26	0.46	-0.69	-0.69	-0.82	-0.67	-0.32	-0.84
Capital Surpluse	0.3	0.4	-0.82	-0.8	0.91	-0.98		-0.56	-0.65	0.24	-0.44	0.67	0.68	0.85	0.71	0.32	0.86
Total Liab	-0.63	-0.73	0.81	0.5	-0.22	0.66	-0.56		0.05	-0.61	-0.18	-0.47	-0.5	-0.36	-0.39	-0.57	-0.43
Net Invested Capital	0.42	0.42	0.15	0.54	-0.82	0.66	-0.65	0.05		0.48	0.96	-0.4	-0.38	-0.49	-0.27	0.12	-0.47
Total Current Assets	0.99	0.89	-0.73	-0.44	0.0	-0.26	0.24	-0.61	0.48		0.66	0.52	0.05	0.4	0.59	0.38	0.45
Net Working Capital	0.61	0.63	-0.1	0.35	-0.69	0.46	-0.44	-0.18	0.96	0.66		-0.23	-0.23	-0.32	-0.08	0.27	-0.29
Common Stock	0.53	0.32	-0.69	-0.98	0.65	-0.69	0.67	-0.47	-0.4	0.52	-0.23		0.03	0.73	0.92	0.09	0.77
Net Receivables	0.13	0.39	-0.59	-0.19	0.53	-0.69	0.68	-0.5	-0.38	0.05	-0.23	0.03		0.39	0.09	0.22	0.38
Short Long Term Debt	0.46	0.39	-0.77	-0.82	0.85	-0.82	0.85	-0.36	-0.49	0.4	-0.32	0.73	0.39		0.78	0.36	1.0
Capital Stock	0.6	0.47	-0.75	-0.92	0.67	-0.67	0.71	-0.39	-0.27	0.59	-0.08	0.92	0.09	0.78		0.14	0.8
Short Term Debt	0.38	0.55	-0.48	-0.17	0.03	-0.32	0.32	-0.57	0.12	0.38	0.27	0.09	0.22	0.36	0.14		0.39
Current Deferred Revenue	0.51	0.43	-0.8	-0.85	0.83	-0.84	0.86	-0.43	-0.47	0.45	-0.29	0.77	0.38	1.0	0.8	0.39

Click cells to compare fundamentals

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(0.23)	(0.24)
Tangible Book Value Per Share	(0.23)	(0.24)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC